Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are associated with loss of nuclear transactive response DNA-binding protein 43 (TDP-43). Here we identify that TDP-43 regulates expression of the neuronal growth-associated factor stathmin-2. Lowered TDP-43 levels, which reduce its binding to sites within the first intron of stathmin-2 pre-messenger RNA, uncover a cryptic polyadenylation site whose utilization produces a truncated, non-functional mRNA. Reduced stathmin-2 expression is found in neurons trans-differentiated from patient fibroblasts expressing an ALS-causing TDP-43 mutation, in motor cortex and spinal motor neurons from patients with sporadic ALS and familial ALS with GGGGCC repeat expansion in the C9orf72 gene, and in induced pluripotent stem cell (iPSC)-derived motor neurons depleted of TDP-43. Remarkably, while reduction in TDP-43 is shown to inhibit axonal regeneration of iPSC-derived motor neurons, rescue of stathmin-2 expression restores axonal regenerative capacity. Thus, premature polyadenylation-mediated reduction in stathmin-2 is a hallmark of ALS-FTD that functionally links reduced nuclear TDP-43 function to enhanced neuronal vulnerability.
A myotrophic lateral sclerosis (ALS) is a late-onset neurodegenerative disease of the motor system, characterized by selective and progressive loss of motor neurons, eventually leading to paralysis and death within 2-5 years 1 . Ninety percent of ALS cases are not associated with a family history and referred to as sporadic ALS. The remaining 10% are caused by inherited mutations in a variety of genes, including the most frequent genetic cause of ALS represented by GGGGCC repeat expansions in the chromosome 9 open reading frame 72 (C9orf72) gene 2, 3 . Notably, many of the genes whose mutation is linked to ALS also cause or contribute to another age-dependent neurodegenerative disorder frontotemporal dementia (FTD). A landmark contribution to understanding cellular mechanisms of ALS and FTD came from the discovery of cytoplasmic accumulation and nuclear loss of the RNA binding protein transactive response DNA-binding protein 43 (TDP-43) from affected neurons in most instances of ALS, as well as in approximately 45% of patients with FTD 4, 5 . Over 40 dominantly inherited mutations in the gene encoding TDP-43 have subsequently been identified in familial ALS patients 6 , implicating TDP-43 dysfunction in the vast majority of ALS cases.
TDP-43 is involved in fundamental RNA processing activities including RNA transcription, splicing, and transport [7] [8] [9] [10] . TDP-43 binds to thousands of pre-messenger RNA/mRNA targets, with high affinity for GU-rich sequences, including autoregulation of its own mRNA via binding to the 3′ untranslated region (3′ UTR) 8, 9, 11 . Reduction in TDP-43 from an otherwise normal adult nervous system alters the splicing or expression levels of more than 1,500 RNAs, including long intron-containing transcripts 8, 12 . Considering the central role of TDP-43 in RNA metabolism, it is anticipated that loss of nuclear TDP-43 in affected neurons of ALS and FTD patients drives processing alterations of multiple RNAs 8, 12 . However, a direct link to neuronal degeneration from reduction or mutation in TDP-43 remains elusive.
Microtubules are key components of the neuronal cytoskeleton, essential for maintaining the stability, shape, and proper function of the neuron 13 . An intrinsic property of microtubules is their 'dynamic instability' 14 , that is, the ability to switch between rapid polymerization and rapid shrinkage (known as catastrophe) in a process that is largely dampened by microtubule-associated proteins 15 . One of these (encoded by the STMN2 gene) is the neuronal stathmin-2 (also known as SCG10), which is thought to play an important role in neurite outgrowth 16 , most likely by promoting microtubule dynamics in axonal growth cones 17, 18 . The four proteins of the stathmin family, each encoded by a different gene, affect microtubule dynamics by either directly promoting catastrophe 19 or sequestering tubulin to prevent assembly 20 . Stathmin-2, the only essential mammalian stathmin 20 , contains two tubulin-binding domains and a conserved N-terminal membrane-anchoring domain containing two palmitoylation sites 16, 20 .
Stathmin-2 is anterogradely transported along axons 21 and has been implicated as an essential component for axonal regeneration 20 . Following axonal injury, stathmin-2 is upregulated and Articles NATuRe NeuRoSCieNCe recruited to growth cones of regenerating axons 22 . Moreover, stathmin-2 has been proposed as an axonal-maintenance factor whose loss accelerates a neuronal degeneration program 21 . In Drosophila, expression of a mutant stathmin causes retraction of motor neurons from innervated neuromuscular junctions 23 .
We now identify that the mRNA encoding stathmin-2 is significantly lost after TDP-43 depletion and in neurons trans-differentiated from multiple patient fibroblasts, each carrying an ALS-causing mutation in TDP-43. Mechanistically, TDP-43 disruption is shown to drive premature polyadenylation and aberrant splicing in intron 1 of stathmin-2 pre-mRNA, producing a non-functional mRNA. Aberrant polyadenylation/splicing of stathmin-2 pre-mRNA is also consistently found in spinal motor neurons and motor cortex of sporadic ALS and C9orf72 ALS patients, supporting stathmin-2 loss of function as a key driver of motor neuron degeneration. Indeed, suppression of TDP-43 or stathmin-2 in iPSC-derived motor neurons leads to inhibition of axonal regeneration after induced damage. Importantly, restoration of stathmin-2 levels rescues axonal regeneration ability in the absence of TDP-43, evidence supporting rescue of stathmin-2 levels as a potential therapeutic approach in neurodegenerative diseases-especially ALS and FTD-affected by TDP-43 proteinopathy.
Results

TDP-43 depletion or disease-causing mutation suppresses stathmin-2.
Two independent strategies were undertaken to manipulate TDP-43 function in a human neuronal cell line: (1) depletion of TDP-43 by short interfering RNA (siRNA) and (2) genome editing with clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 (Cas9) to introduce an ALS-causing mutation into both endogenous TDP-43 gene loci. The human neuronal cell line SH-SY5Y was chosen as a model as it has been shown to maintain a diploid karyotype and acquire substantial neuronal character when differentiated 24 . siRNA treatment reduced TDP-43 mRNA levels by > 80% when compared with cells treated with a control siRNA (Fig. 1a ). The consequences of lowering TDP-43 were then examined on a genome-wide basis. Libraries of RNAs were prepared, sequenced, and mapped to the human genome. This approach confirmed reduction of TDP-43 to one-fourth of its initial level ( Fig. 1b ). Amid 299 and 219 mRNAs that were down-or upregulated, respectively (with fold changes > 1.5, false discovery rate (FDR) < 0.05) ( Supplementary  Table 1 ), the most affected mRNA (with > 85% reduction; Fig. 1b and Supplementary Fig. 1a ) was the one encoding the neuronal growth-associated protein stathmin-2 16, 18 . Reduction in stathmin-2 mRNA upon TDP-43 depletion was confirmed by quantitative PCR (qPCR) ( Fig. 1c ) and an 8-fold reduction of the 22 kD stathmin-2 protein was identified by immunoblotting ( Fig. 1d and Supplementary Fig. 1b ).
Using a CRISPR-Cas9 site-selective nuclease, we next genetically engineered SH-SY5Y cells to express a familial ALS-causing mutation (asparagine substituted to serine at amino acid 352-TDP-43 N352S ) from both endogenous TDP-43 alleles ( Supplementary  Fig. 2a ). Immunofluorescence imaging confirmed that mutant TDP-43 protein remained mostly nuclear, similar to wild-type TDP-43 expressed in the original SH-SY5Y line ( Fig. 1e and Supplementary  Fig. 2b ). Transcriptional profiling by RNA sequencing (RNA-seq) of the wild-type and mutant lines revealed that introduction of the disease-causing TDP-43 mutation led to altered expression of 950 mRNAs (451 downregulated and 499 upregulated; fold change > 1.5, FDR < 0.05) ( Supplementary Table 2 ), including moderate reduction in TDP-43 ( Fig. 1f ). In addition, previously described alternative splicing changes linked to TDP-43 loss of function were observed in TDP-43 mutant-expressing cells ( Supplementary Fig. 2c ), consistent with both loss of normal TDP-43 function and a gain of aberrant function, as seen previously in mice [25] [26] [27] .
Analysis of RNAs from isogenic wild-type and mutant lines (using qPCR) confirmed a 1.7-fold reduction of stathmin-2 mRNA ( Fig. 1g ), while immunoblotting revealed more than 2-fold reduction of stathmin-2 protein in TDP-43 N352S mutant cells ( Supplementary Fig. 2d ). A search for gene expression changes that overlapped between cells with TDP-43 loss of function ( Fig. 1b ) and TDP-43 N352S mutant cells ( Fig. 1f ) identified stathmin-2 mRNA (and 18 additional RNAs) to be downregulated, together with another 23 that were upregulated ( Fig. 1h ).
Reduced stathmin-2 in TDP-43 mutant human neurons. We then tested whether stathmin-2 expression was reduced in human neurons directly converted from ALS patients' fibroblasts. To this end, we used eight fibroblast lines obtained from an extended family that included four carriers heterozygous for the ALS-linked mutant TDP-43 N352S and four individuals without the mutation (Supplementary Fig. 3a and Supplementary Table 3 ). Overall, stathmin-2 mRNA levels were already reduced (by 50%) ( Supplementary  Fig. 3b ) in the mutant fibroblast lines relative to controls despite primarily nuclear localization of TDP-43 protein both in control and ALS patient fibroblasts ( Supplementary Fig. 3c,d ). Fibroblasts from all eight lines were directly induced into neurons (herein referred to as iNeurons) 28 by expression of the neuronal-specific transcription activator Brn2 and reduction of the polypyrimidine track binding protein (PTB) ( Fig. 2a ).
TDP-43 was almost exclusively nuclear in wild-type and mutant fibroblasts ( Supplementary Fig. 3c,d ). When converted into iNeurons, a higher proportion of wild-type TDP-43 accumulated in the cytoplasm and this relocalization was enhanced in iNeurons expressing the N352S mutation ( Fig. 2b and Supplementary Fig. 3e ). Importantly, stathmin-2 mRNA was significantly downregulated (more than threefold) in all four sets of TDP-43 N352S iNeurons relative to the four iNeuron lines derived from fibroblasts of healthy family members (P < 0.01, n = 4; Fig. 2c ).
We next tested iNeurons generated from familial ALS patient fibroblasts carrying three other mutations: glycine to serine at position 298 (TDP-43 G298S ), alanine to threonine at position 382 (TDP-43 A382T ), and asparagine to serine at position 390 (TDP-43 N390S ). Stathmin-2 mRNA was reduced (relative to iNeurons from non-ALS individuals) in all of these familial ALS iNeurons ( Fig. 2c,d ). These data demonstrate that, similar to reduction of TDP-43, ALSlinked mutations in TDP-43 suppress stathmin-2 expression level in human iNeurons. TDP-43 represses premature polyadenylation in stathmin-2 pre-mRNA. The stathmin-2 gene is annotated to contain five constitutive exons (Refseq ID: NM_001199214.1) plus a proposed alternative exon between exons 4 and 5 whose use was undetectable (using RNA-seq) under any condition in our SH-SY5Y cells ( Fig. 3a ). Reduction or mutation in TDP-43, however, induced a new spliced exon, with RNA-seq reads mapping within intron 1 (Fig. 3a , red arrow). This new exon, herein called 'exon 2a' , was absent in wildtype cells, but appeared either when TDP-43 was depleted or when endogenous TDP-43 was edited to carry the N352S mutation. Prominent utilization of this new exon was observed when TDP-43 was reduced, in line with more than six-fold suppression of RNAs containing exons 2 to 5 ( Fig. 3a , upper panel). This was accompanied by the corresponding loss of stathmin-2 protein ( Fig. 1d and Supplementary Fig. 1b ).
Altered splicing and ligation of exon 1 to exon 2a in SH-SY5Y cells after TDP-43 depletion or in the presence of a TDP-43 mutation was then confirmed by reverse transcription followed by PCR (RT-PCR) and qPCR ( Fig. 3b ). However, while fusion between exon 1 and exon 2a was consistently observed (Fig. 3b ), no RNAs containing exon 2a ligated to the downstream exon 2 were identified using primers targeting the flanking exons 1 and 2 ( Supplementary Fig. 4a -c). 
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To test the possibility that incorporation of exon 2a drives alternative polyadenylation within what is normally intron 1 (Fig. 3c ), we used anchored oligo(dT) primers for reverse transcription followed by PCR and sequencing. This analysis confirmed polyadenylation of the stathmin-2 RNA containing exon 2a as the terminal exon ( Fig. 3d ,e). A polyadenylation signal ' AUUAAA' 29 was identified 24 nucleotides upstream to the polyadenylation site ( Fig. 3d ). This cryptic polyadenylation sequence in the human stathmin-2 gene is conserved among most primates, but is notably absent in mouse or rat ( Supplementary Fig. 4d ). qPCR analysis on nascent stathmin-2 pre-mRNAs identified reduction in full-length stathmin-2 transcripts in SH-SY5Y cells expressing mutant TDP-43 ( Supplementary Fig. 4e ), consistent with increased levels of truncated exon 2a-containing RNAs (Fig. 3b ).
The prematurely polyadenylated RNA includes 227 nucleotides originating from exon 2a (hg38; chr8:79,616,822-79,617,048) with its predicted 16 amino acid translation product initiating at the normal AUG codon in exon 1 and ending 11 codons into exon 2a ( Fig. 3c,d ). Three 'GUGUGU' hexamers marking potential binding sites of TDP-43 (as we and others have previously described 8, 9 ) were identified in a region spanning 30 nucleotides downstream of the 3′ splice site that produces exon 2a ( Fig. 3d ). Indeed, analysis of ultraviolet cross-linking and immunoprecipitation (iCLIP) data for TDP-43 in human SH-SY5Y cells 9 confirmed TDP-43 binding (shown by mapped reads) to the stathmin-2 pre-mRNA at a single region containing the three GUGUGU sequences ( Fig. 3f ), thus confirming physical interaction with TDP-43 protein. Altogether, we conclude that reduction in TDP-43 causes de-repression and efficient use of a cryptic polyadenylation site in what normally is intron 1, which results in truncation of the stathmin-2 pre-mRNA and suppression of functional stathmin-2 expression.
Stathmin-2 mRNA is prominently expressed in motor neurons.
Comparison of published evidence of the abundance of stathmin-2 mRNA in ribosome-bound RNAs across specific cell types of the a, Summary of the direct conversion strategy adopted from Xue et al. 28 . b, iNeurons produced by direct conversion from fibroblasts of control and ALS patients. Immunofluorescence staining at day 20 of differentiation revealed partial cytoplasmic mislocalization of TDP-43 (green) in ALS iNeurons. Neuron-specific class III β -tubulin (Tuj1, red) was used as a neuronal marker; cell nuclei were visualized by DAPI staining (blue). The experiment was repeated independently with similar results from three control individuals and three familial ALS donor lines (with mutant TDP-43). c, qPCR analysis of stathmin-2 mRNA levels in iNeurons from control (gray bars, black dots) and familial ALS patients with different TDP-43 mutations (white bars, turquoise dots). Plotted are two biologically independent experiments per each individual from an extended family that included four carriers heterozygous for the ALS-linked mutant TDP-43 N352S (n = 4, mean = 0.3) and four individuals without the mutation (n = 4, mean = 1). Two-tailed t test, P = 0.008. Also plotted are three biologically independent experiments of three additional ALS patients (nonfamily members) with the indicated mutations. a Asymptomatic. d, Summary of stathmin-2 expression level measured by qPCR in iNeurons from controls (n = 4, gray, mean = 1) and familial ALS patients (n = 7, white, mean = 0.36). P = 0.0005, two-tailed t test. Error bars represent s.e.m. **P < 0.01; ***P < 0.001.
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NATuRe NeuRoSCieNCe murine central nervous system 30 revealed 25-and 15-fold enrichment of translated stathmin-2 mRNAs in motor neurons relative to astrocytes and oligodendrocytes, respectively ( Supplementary  Fig. 5a ). Remarkably, further analysis of these data 31 identified stathmin-2 to be among the 25 most abundant actively translated mRNAs isolated from adult motor neurons in mice. Similarly, our analysis of RNA sequencing from laser capture microdissected human lumbar spinal motor neurons from seven healthy controls 31 determined that in human spinal motor neurons stathmin-2 is the 20th most abundant mRNA, only slightly less abundant than the mRNAs encoding the three neurofilament subunits NF-L, NF-M, and NF-H ( Supplementary Fig. 5b ). Further, of the four stathmin genes, only stathmin-2 was enriched within human motor neurons ( Supplementary Fig. 5c ). Supplementary Fig. 10 . e,f, Lumbar spinal cord and motor cortex sections isolated from control individuals and sporadic ALS patients were hybridized with locked nucleic acid probes targeting exon 2a (within intron one) of stathmin-2 pre-mRNA (for the truncated RNA) or exon 5 of stathmin-2 pre-mRNA. Signal is shown in blue, counterstain is nuclear fast red. g, Summary of human samples with expression of stathmin-2 truncated RNA, identified by RT-PCR or in situ hybridization. Data shown in Supplementary Fig. 7 are included in this table. NA, not applicable.
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Suppression of stathmin-2 by premature polyadenylation is a hallmark of ALS. Analysis of the RNA sequencing reads mapping to the stathmin-2 gene from lumbar motor neurons captured by laser microdissection revealed a clear segregation between controls and sporadic ALS cases. RNAs from all analyzed sporadic ALS patients (n = 13) contained inclusion of exon 2a ( Fig. 4a and Supplementary Fig. 6 ). In contrast, RNAs including exon 2a were absent in mRNA from all tested (n = 7) non-ALS individuals. Importantly, just as we had determined in TDP-43 mutant expressing SH-SY5Y cells and patient-derived iNeurons ( Figs. 1 and 2) , overall stathmin-2 mRNA levels in sporadic ALS patients were significantly decreased relative to those in motor neurons from non-ALS individuals (Fig. 4b) . By contrast, stathmin-1 mRNA expression was low in both healthy and ALS spinal motor neurons ( Fig. 4b) . Additionally, analysis of RNAs extracted from anterior horns of thoracic spinal cord from 13 sporadic ALS patients and three familial ALS patients carrying GGGGCC expansion in C9orf72 revealed aberrant processing of stathmin-2 mRNA in all, but not in RNAs from eight healthy individuals or three familial ALS patients with superoxide dismutase 1 (SOD1) mutations ( Fig. 4c and Supplementary Fig. 7a ). Consistent with the latter, mice developing fatal motor neuron disease from expression of an ALSlinked mutation in SOD1 retained normal stathmin-2 mRNA levels despite apparent motor neuron damage 30 , demonstrating that stathmin-2 expression is not affected by motor neuron degeneration per se ( Supplementary Fig. 5a ). Recognizing that TDP-43 pathology is found in sporadic and familial ALS linked to C9orf72 expansion 32 but not SOD1-mediated ALS ( Supplementary Fig. 8 ) 33 , these results are consistent with premature polyadenylation of stathmin-2 mRNA being triggered by TDP-43 dysfunction and the corresponding suppression of stathmin-2 expression in both thoracic ( Fig. 4c and Supplementary Fig. 7a ) and lumbar (Fig. 4a ) motor neurons. Extension of similar analyses to the motor cortex identified altered processing of stathmin-2 mRNA to include exon 2a in two of two C9orf72 samples and six of nine sporadic ALS samples (Fig. 4d ). For ALS cases that were also diagnosed with FTD, premature polyadenylation was seen in frontal cortex-derived RNAs in three of four sporadic ALS-FTD patients, and one of one C9orf72 expansion patient ( Supplementary Fig. 7b ).
Lastly, chromogenic in situ hybridization was used to test on a cell-by-cell basis for stable accumulation of exon 2a-containing stathmin-2 RNAs in spinal cord and motor cortex samples from five control individuals and four sporadic ALS patients ( Fig. 4e-g and Supplementary Fig. 7c,d ). In agreement with prior analyses of RNAs derived by laser microdissection (Fig. 4a ) or from bulk tissues ( Fig. 4c,d) , RNA probes hybridizing to stathmin-2 exon 2a were increased in both nuclear and cytoplasmic compartments of spinal cord neurons (97% of sporadic ALS motor neurons versus 0% of control; n = 69 and 41, respectively) and in neurons from layers 3 and 5 of motor cortex from all ALS-derived samples, with 100% of scored sporadic ALS cortical neurons staining positive for exon 2a (n = 50) versus 0% of control cortical neurons (n = 50). Low basal levels of hybridization (presumably corresponding to the newly transcribed stathmin-2 pre-mRNA) were found in tissues from non-ALS individuals, with an intensity only slightly above that of a scrambled sequence control probe.
A probe hybridizing to exon 5 of the stathmin-2 mRNA revealed an apparent reduction in affected regions of sporadic ALS, with only 35% of sporadic ALS lumbar motor neurons showing weakly positive staining for STMN2 exon 5 versus 70% of control non-ALS motor neurons (n = 65 and 61, respectively). The reduction of exon 5 staining was even more substantial in the motor cortex where 0% of scored neurons showed a positive signal, compared with a strong signal in 100% of non-ALS cortical neurons (Fig. 4e,f and Supplementary Fig. 7c,d) .
Impaired axonal regeneration on TDP-43 loss in human iPSCderived motor neurons is alleviated by restoring stathmin-2.
To determine the functional consequence of TDP-43-mediated reduction in stathmin-2, induced pluripotent stem cells (iPSCs) were generated using a non-integrating approach, validated to retain a normal karyotype ( Supplementary Fig. 9a ) and expression of pluripotent stem cell markers ( Supplementary Fig. 9b-d) , and differentiated into motor neurons ( Supplementary Fig. 9e ). Motor neuron precursors (expressing homeobox gene HB9) appeared within 21 days ( Supplementary Fig. 9f ) and by 28 days developed MAP2-positive dendrites and long axons accumulating neurofilaments ( Supplementary Fig. 9g,h) . At day 29, motor neurons were treated with antisense oligonucleotides (ASOs) that direct catalytic Supplementary Fig. 10 . c, Quantitative real-time PCR analysis confirming ASO-mediated reduction of stathmin-2 mRNA (red; dose-dependent mean values are 0.23, 0.12, and 0.07, respectively) or TDP-43 mRNA (gray; dose-dependent mean values are 0.99, 0.95, and 1.04, respectively) levels in human iPSC-derived motor neurons. Control bar (mean = 1) represents three biological replicates; expression of TFRC mRNA was used as endogenous control. Error bars represent s.e.m. d, Immunoblotting of TDP-43 and stathmin-2 in iPSC-derived motor neurons treated with mouse Malat-1 ASO as control (n = 2 biologically independent experiments), TDP-43 ASO (n = 2 biologically independent experiments) or stathmin-2 ASO (n = 2 biologically independent experiments) for 20 days. α -Tubulin served as a loading control. Stathmin-2 was profoundly suppressed following TDP-43 ASO or stathmin-2 ASO treatments. Experiment was repeated independently five times with similar results. For uncropped blots, see Supplementary Fig. 10 . e, Schematic of motor neurons cultured in microfluidic chambers before and after axotomy. Motor neuron precursors (pre-MNs) were plated at the somatic or proximal compartment and axons reached into the distal or axonal compartment during a maturation period of another 8 days. ASOs were then added to the somatic compartment with a second dose after 12 days. After 20 days of culturing with ASOs, aspiration-based axotomy was performed at the distal compartment of each chamber leading to a complete removal of axons in that compartment. Recovery was allowed for 24 h. f, Timeline of iPSC-derived motor neuron maturation, ASO treatment, and axotomy is shown. g,i,k,m,o, Representative confocal immunofluorescence images of microgrooves and distal compartments, 24 h after axotomy. Insets show high-magnification view of regenerating axons' growth cones. Axonal regeneration and growth cones were observed by immunofluorescence of stathmin-2 (green) and NF-H (red) in the terminals of motor neurons treated with control ASOs (g,h) but not in motor neurons treated with stathmin-2 (i,j) or TDP-43 (k,l) ASOs. m-p, iPSCs-derived motor neurons treated with ASOs against stathmin-2 (m,n) or TDP-43 (o,p) for 20 days and transduced with stathmin-2 expressing lentivirus for the last 96 h showed axonal regeneration with growth cones in all axonal terminals. h,j,l,n,p, Quantifications of 300 axons per condition are shown.
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ASO-induced reduction in TDP-43 mRNA (up to 55%) was consistently accompanied by a greater (up to 12-fold) dose-dependent reduction in stathmin-2 mRNAs, coupled with a corresponding increase in RNAs containing exon 1 ligated to exon 2a (Fig. 5b) . Dose-dependent suppression (up to 15-fold) of stathmin-2 expres-sion in iPSC-derived motor neurons (without affecting TDP-43 levels) was also achieved with an ASO targeted to the 3′ UTR of full-length stathmin-2 mRNA (Fig. 5c ). Immunoblotting confirmed that within 12 days of treatment with ASOs targeting either TDP-43 or stathmin-2 mRNAs there was nearly complete loss of the 22 kD stathmin-2 protein (Fig. 5d ). Motor neuronal viability was not affected by reduction in either TDP-43 or stathmin-2 ( Supplementary Fig. 9i ). 
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To assess the functional consequences of stathmin-2 depletion in axonal regeneration (Fig. 5e ), motor neuron precursors were seeded into the proximal somatic compartment of a microfluidic device. Over a 9 day maturation period, axons extended through microgroove-embedded channels (830 μ m in length) that exclude neuronal cell bodies but allow axonal extension into the distal compartment. Matured motor neurons were treated for 20 days with ASOs added to the somatic compartment to reduce synthesis and accumulation of either TDP-43 or stathmin-2 (Fig. 5f ). Axons were maintained after loss of either protein. After axons in the distal compartment were mechanically axotomized, axonal regrowth of motor neurons treated with nontargeting control ASOs initiated within 24 h (visualized by NF-H immunostaining in red; Fig. 5g,h) . Stathmin-2 appeared in a punctate pattern along these regenerating axons and accumulated in the growth cones (Fig. 5g) , consistent with a role in promoting axonal regrowth. Indeed, following ASO-mediated reduction in stathmin-2 (Fig. 5i,j) or TDP-43 (Fig. 5k,l) , axonal regeneration after axotomy was almost completely suppressed, with 10% ( Fig. 5j ) and 13% (Fig. 5l ) recovery rates relative to those treated with control ASOs, respectively. Together, these data demonstrate increased vulnerability of motor neurons with reduced accumulation of the neuronal-growth factor stathmin-2.
We next tested whether the failure to regenerate after axotomy of iPSC-derived human motor neurons following depletion of either stathmin-2 or TDP-43 could be rescued by restoration of stathmin-2 expression. To do this, after a 16 day ASO-mediated suppression of stathmin-2 or TDP-43, iPSC-derived motor neurons were transduced with a lentivirus carrying a stathmin-2-encoding gene whose RNA did not contain the cryptic polyadenylation site found in the endogenously encoded stathmin-2 gene. Despite the prior sustained (16 days) reduction in stathmin-2, subsequent restoration of stathmin-2 expression almost completely rescued regeneration after axotomy (Fig. 5m,n) . More remarkably, although TDP-43 affects the levels or splicing of many RNAs (Fig. 1b and refs. 8, 9 ) , restoration of stathmin-2 alone was sufficient to rescue regeneration after axotomy of TDP-43 depleted motor neurons (Fig. 5o,p ).
Discussion
Using three independent approaches, we have identified that reduction or mutation in TDP-43 induces aberrant processing of stathmin-2 pre-mRNA, leading to efficient usage of a cryptic polyadenylation site that truncates mRNAs encoding stathmin-2, thereby suppressing stathmin-2 synthesis. Our data strongly support that under normal conditions TDP-43 acts to maintain stathmin-2 expression by repressing this premature polyadenylation within intron 1 of the stathmin-2 pre-mRNA. Loss of nuclear TDP-43 is a nearly universal pathological hallmark in ALS, and notably, we observed efficient premature polyadenylation of stathmin-2 in motor neurons of all tested sporadic ALS patients and in patients with repeat expansion in C9orf72, the most common inherited cause of ALS and FTD. In contrast, altered processing of stathmin-2 was not found in SOD1 ALS patients who do not exhibit TDP-43 pathology. Thus, our data offer strong support that loss of stathmin-2 RNA by premature polyadenylation and subsequent reduced levels of stathmin-2 protein in affected neurons are hallmarks of sporadic and C9orf72-expansion-mediated ALS and FTD.
Thousands of mRNA targets affected by TDP-43 dysfunction have been identified in multiple cell lines and in vivo 8, 9, 11, 25 . Notably, reduced TDP-43 has been linked to the abnormal inclusion of a set of cryptic exons that may lead to nonsense-mediated decay and reduced levels of transcripts in different cell types and tissues from mouse and human 10, [34] [35] [36] . To that, we have established here that TDP-43 also acts in the normal situation to suppress polyadenylation within exon 2a in stathmin-2 pre-mRNA. Reduced TDP-43 in human motor neurons is accompanied by nearly complete loss of expression of functional stathmin-2. Recognizing that splicing typically occurs co-transcriptionally 37 , it is likely that the premature polyadenylation in stathmin-2 mRNA is the driving event in stathmin-2 suppression, with premature polyadenylation inducing the splicing machinery to use a previously cryptic 3′ site to resolve splicing initiated at the normal 5′ splice site in intron 1.
We note that abnormal processing of stathmin-2 is not recapitulated in mice expressing TDP-43 transgenes or in TDP-43 deficient mice, as the cryptic polyadenylation signal and three GU-rich TDP-43 binding sites in intron 1 of the human stathmin-2 gene are not found in the corresponding mouse intron ( Supplementary Fig. 4d ). Consistently, stathmin-2 pre-mRNA is not bound by TDP-43 in the murine nervous system and stathmin-2 mRNA level is not altered after ASO-mediated reduction of TDP-43 in wild-type mice 8 . By mining TDP-43 iCLIP data 9 , we have identified physical interaction of TDP-43 with the GU-rich sequences in exon 2a of human stathmin-2 pre-mRNA. This strongly supports that in healthy neurons, TDP-43 binding represses premature polyadenylation of stathmin-2 pre-mRNA. TDP-43 loss of function during disease relieves this inhibition, producing exon 2a-containing, truncated stathmin-2 mRNAs as seen in all sporadic and C9orf72-mediated ALS examples tested here.
Our evidence supports a broader role for TDP-43 in modulating polyadenylation within the nervous system, similar to the role previously shown for the neuronal factor Nova 38 , as well as additional RNA-binding proteins 39, 40 including the ALS-associated protein FUS 12, 41 . Since computational analysis has recently identified extensive alternative polyadenylation in cerebellum of C9orf72 ALS and sporadic ALS subjects 42 , as well as in HEK293 cells with TDP-43 suppression 43 , the global impact of TDP-43 on alternative polyadenylation in human motor neurons should now be determined.
Impaired microtubule dynamics has been widely implicated in neurodegeneration, and microtubule-stabilizing agents have been proposed as a therapeutic approach 44 . While disruption of TDP-43 nuclear function affects the processing of numerous RNA targets, our data provide a link between increased motor neuron vulnerability in ALS and suppression of stathmin-2, a tubulin binding protein previously established to affect microtubule dynamics 18 . The family of vertebrate stathmins includes stathmins 1-4 that are likely to serve both complementary and distinct functions in the nervous system 20 . Each stathmin possesses two conserved tubulin-binding domains that are capable of interacting with two α /β tubulin heterodimers 20 .
Individual stathmins may have unique functional properties. Stathmin-2 and -4 are highly expressed in neurons 16 , with only stathmin-2 mRNA enriched in motor neurons ( Supplementary  Fig. 5b, c) . Increased expression of stathmin-1 and -2 has been reported in cellular and mouse models of spinal muscular atrophy 45 and in motor neurons of spinal muscular atrophy-like mice 45 and ALS mice expressing mutant SOD1 46, 47 . Stathmin-2 has been proposed as a neuronal regeneration marker 22 (with expression similar to the axonal growth associated protein GAP-43 48 ) and we have shown here that axonal regeneration after reduction in TDP-43 can be restored by maintaining stathmin-2 levels (Fig. 5 ). In contrast, reduction in stathmin-1, which we show to be expressed in motor neurons at 1/30th the level of stathmin-2 (Fig. 4b) , has been reported to rescue axonal pathology in motor neurons in pmn mice that have mutation in the TBCE chaperone for folding tubulin 49 .
The stathmin-2 loss we have identified in motor neurons from ALS patients is strongly expected to alter microtubule dynamics and function, thereby contributing to denervation from neuromuscular junctions and/or axonal degeneration. This scenario is supported by evidence of destabilized neuromuscular junctions and impaired synapse stability in Drosophila expressing mutant stathmin 23 . Likewise, a paralytic phenotype was reported following loss of stathmin function in Drosophila 50 . The high level of stathmin-2
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To this, our data provide evidence that reduction in stathmin-2, as the consequence of neuronal damage or stress that leads to diminished nuclear TDP-43 function, is itself sufficient to inhibit regeneration of motor axons. Restoring the regenerative capability to iPSC-derived motor neurons depleted of TDP-43 simply by restoring stathmin-2 levels offers a new insight into how TDP-43 dysfunction drives increased neuronal vulnerability. Perhaps most importantly, our evidence supports development of therapeutic strategies for ALS, FTD, and other neurodegenerative diseases affected by TDP-43 proteinopathy through restoration of stathmin-2 to increase sustainability, including regenerative capacity of affected neurons.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41593-018-0293-z. Compartmentalized microfluidic devices and axotomy. The master molds to prepare the microfluidic devices were fabricated by photolithography, as previously described 56 , by the Bioengineering Department of the University of California, San Diego, Nano3 Cleanroom Facility. Two compartment devices were molded by soft lithography using Sylgard 182 (Ellsworth Adhesives) as previously described 57 .
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Each compartment of the device was 108 μ m tall, separated by microgrooves 3.1 μ m tall, 16.28 μ m wide, and 830 μ m long. The proximal compartment contained one hole in each side of the compartment 8 mm in diameter, while the distal compartment's holes were 4 mm in diameter. These characteristics are important to perform an effective vacuum-based axotomy. After curing, the cut devices were bath-sonicated in water, washed in 70% ethanol and sterilized under ultraviolet light before mounting onto glass coverslips. The devices were coated with matrigel (Corning, 356230) for 1 h at 37 °C and rinsed with DMEM before plating the cells. Half a million iPSC-derived motor neuron precursors were plated in the proximal somatic compartment, and axonal growth to distal compartment was achieved in 8 d of maturation. ASOs were then added into the somatic compartment for 20 d of treatment, half media was changed every 4 d and a second dose of ASOs was added after 12 d. For aspiration-induced axotomy, media was simultaneously aspirated from one side and added back to the other side of the distal (axonal) compartment, until complete removal of axons from the distal compartment was confirmed. 
Statistical parameters
When statistical analyses are reported, confirm that the following items are present in the relevant location (e.g. figure legend, table legend, main text, or Methods section).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement An indication of whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data analysis
Fiji/Image J software (version 2.0.0-rc-68/1.52e) was used to analyze confocal raw files, GraphPad Prism (version 5.0a) was used for statistical analyses. Bioinformatics: RNA sequencing analysis was performed using STAR (version 2.5.3a with default setting) and RSEM (version 1.3.0 with default setting). Differentially expressed genes were determined using DESeq2 (version 1.14.1). For more information see Methods.
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